Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xencor Inc (XNCR)

Xencor Inc (XNCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 837,531
  • Shares Outstanding, K 73,339
  • Annual Sales, $ 125,580 K
  • Annual Income, $ -91,920 K
  • EBIT $ -178 M
  • EBITDA $ -170 M
  • 60-Month Beta 0.95
  • Price/Sales 7.19
  • Price/Cash Flow N/A
  • Price/Book 1.38

Options Overview Details

View History
  • Implied Volatility 252.11% (-97.99%)
  • Historical Volatility 71.05%
  • IV Percentile 75%
  • IV Rank 51.33%
  • IV High 440.78% on 09/10/25
  • IV Low 53.12% on 08/18/25
  • Expected Move (DTE 19) 0.43 (3.72%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 16
  • Volume Avg (30-Day) 21
  • Put/Call OI Ratio 1.52
  • Today's Open Interest 361
  • Open Int (30-Day) 336
  • Expected Range 11.00 to 11.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.65
  • Number of Estimates 8
  • High Estimate 0.01
  • Low Estimate -0.91
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +1.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.62 +7.53%
on 03/06/26
13.30 -14.12%
on 03/02/26
-1.35 (-10.57%)
since 02/27/26
3-Month
10.62 +7.53%
on 03/06/26
15.42 -25.94%
on 12/31/25
-3.80 (-24.97%)
since 12/26/25
52-Week
6.92 +65.03%
on 08/11/25
18.69 -38.90%
on 12/05/25
-0.09 (-0.78%)
since 03/27/25

Most Recent Stories

More News
Stocks Settle Lower as Iran War Boosts Crude Oil and Bond Yields

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.77%. June E-mini...

MSTR : 126.03 (-5.19%)
SOLV : 62.76 (-3.01%)
MPC : 251.91 (+1.45%)
DG : 117.16 (-1.74%)
INTU : 416.44 (-3.72%)
DDOG : 114.48 (-7.90%)
GLXY : 18.00 (-8.21%)
SLB : 53.50 (+2.27%)
XNCR : 11.42 (-7.23%)
$IUXX : 23,132.77 (-1.93%)
COIN : 161.14 (-7.06%)
FICO : 1,011.06 (-2.77%)
Stocks Fall as Iran War Drags On

The S&P 500 Index ($SPX ) (SPY ) today is down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.50%. June E-mini S&P futures (ESM26...

MSTR : 126.03 (-5.19%)
APO : 108.42 (-1.42%)
ARES : 106.28 (-1.52%)
MPC : 251.91 (+1.45%)
DG : 117.16 (-1.74%)
GLXY : 18.00 (-8.21%)
COIN : 161.14 (-7.06%)
FANG : 201.84 (-0.17%)
NTGR : 21.57 (-2.53%)
^BTCUSD : 66,653.32 (+0.98%)
SPY : 634.09 (-1.71%)
ADSK : 229.84 (-4.17%)
Stocks Pressured as Crude Oil Prices and Bond Yields Climb

The S&P 500 Index ($SPX ) (SPY ) today is down -0.80%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.83%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.98%. June E-mini S&P futures...

APO : 108.42 (-1.42%)
BLK : 933.85 (-3.57%)
SOLV : 62.76 (-3.01%)
ARES : 106.28 (-1.52%)
DG : 117.16 (-1.74%)
INTU : 416.44 (-3.72%)
DDOG : 114.48 (-7.90%)
XNCR : 11.42 (-7.23%)
$IUXX : 23,132.77 (-1.93%)
FICO : 1,011.06 (-2.77%)
ZNM26 : 110-050s (-0.01%)
SFD : 26.69 (+3.33%)
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals,...

XNCR : 11.42 (-7.23%)
Xencor: Q4 Earnings Snapshot

Xencor: Q4 Earnings Snapshot

XNCR : 11.42 (-7.23%)
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

-- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track to present clinical data to support a recommended...

XNCR : 11.42 (-7.23%)
Xencor to Participate at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will...

XNCR : 11.42 (-7.23%)
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026...

XNCR : 11.42 (-7.23%)
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

-- Royalty term on Ultomiris® sales in the United States anticipated to continue into year-end 2028, extending term by three years -- -- Additional $100 million to $120 million in potential royalty...

XNCR : 11.42 (-7.23%)
Xencor to Participate at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will...

XNCR : 11.42 (-7.23%)

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

3rd Resistance Point 13.25
2nd Resistance Point 12.83
1st Resistance Point 12.12
Last Price 11.42
1st Support Level 10.99
2nd Support Level 10.57
3rd Support Level 9.86

See More

52-Week High 18.69
Fibonacci 61.8% 14.19
Fibonacci 50% 12.81
Fibonacci 38.2% 11.42
Last Price 11.42
52-Week Low 6.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.